Tixagevimab-cilgavimab reduced risk for severe COVID-19 progression in patients with hematologic malignancies on anti-CD20 therapy during the early Omicron era.
The previously-unknown condition, dubbed 'post-vaccination syndrome' (PVS), can persist years after taking the jabs - made by ...
Adults aged more than 70 who received more prescriptions for nirmatrelvir-ritonavir did not show decreased rates of ...
Department of Health and Human Services Secretary Robert F. Kennedy Jr. paused a $240 million contract to create a new coronavirus vaccine.
Exploring alternative vaccine delivery systems could increase accessibility and encourage those who fear needles to receive ...
In a small study, Yale researchers have found "differences in immune profiles" among those who have rare reaction to the ...
I could discuss risks and benefits in a more sophisticated way if I better understood a patient’s risk versus their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback